Improvement of peripheral neuropathy using LEDs

[Guest guest]

Restoration of sensation, reduced pain, and improved balance in subjects

with diabetic peripheral neuropathy: a double-blind, randomized,

placebo-controlled study with monochromatic near-infrared treatment.

_http://www.ncbi.nlm.nih.gov/pubmed/14693984_

(http://www.ncbi.nlm.nih.gov/pubmed/14693984)

Leonard DR, Farooqi MH, Myers S.

Source: Joslin Center for Diabetes, Morton Plant Mease Healthcare,

Clearwater, Florida 33756, USA.

Abstract

OBJECTIVE:

Diabetic peripheral neuropathy (DPN) has been thought to be progressive

and irreversible. Recently, symptomatic reversal of DPN was reported after

treatments with a near-infrared medical device, the Anodyne Therapy System

(ATS). However, the study was not controlled nor was the investigator

blinded. We initiated this study to determine whether treatments with the ATS

would decrease pain and/or improve sensation diminished due to DPN under a

sham-controlled, double-blind protocol.

RESEARCH DESIGN AND METHODS:

Tests involved the use of the 5.07 and 6.65 Semmes Weinstein monofilament

(SWM) and a modified Michigan Neuropathy Screening Instrument (MNSI).

Twenty-seven patients, nine of whom were insensitive to the 6.65 SWM and 18 who

were sensitive to this filament but insensitive to the 5.07 SWM, were

studied. Each lower extremity was treated for 2 weeks with sham or active ATS,

and then both received active treatments for an additional 2 weeks.

RESULTS:

The group of 18 patients who could sense the 6.65 SWM but were insensitive

to the 5.07 SWM at baseline obtained a significant decrease in the number

of sites insensate after both 6 and 12 active treatments (P < 0.02 and

0.001). Sham treatments did not improve sensitivity to the SWM, but subsequent

active treatments did (P < 0.002). The MNSI measures of neuropathic

symptoms decreased significantly (from 4.7 to 3.1; P < 0.001). Pain reported on

the 10-point visual analog scale decreased progressively from 4.2 at entry to

3.2 after 6 treatments and to 2.3 after 12 treatments (both P < 0.03). At

entry, 90% of subjects reported substantial balance impairment; after

treatment, this decreased to 17%. However, among the group of nine patients

with

greater sensory impairment measured by insensitivity to the 6.65 SWM at

baseline, improvements in sensation, neuropathic symptoms, and pain reduction

were not significant.

CONCLUSIONS:

ATS treatments improve sensation in the feet of subjects with DPN, improve

balance, and reduce pain.

[Guest guest]

Here is the whole study with references in a pdf file.

Restoration of Sensation, Reduced Pain, and Improved Balance in Subjects

With Diabetic Peripheral Neuropathy

A double-blind, randomized, placebo-controlled study with monochromatic

near-infrared treatment -- includes References

_http://care.diabetesjournals.org/content/27/1/168.full.pdf_

(http://care.diabetesjournals.org/content/27/1/168.full.pdf)

blessings

Shan

In a message dated 13/02/2012 7:38:50 P.M. Eastern Standard Time,

SurpriseShan2@... writes:

Restoration of sensation, reduced pain, and improved balance in subjects

with diabetic peripheral neuropathy: a double-blind, randomized,

placebo-controlled study with monochromatic near-infrared treatment.

_http://www.ncbi.nlm.nih.gov/pubmed/14693984_

(http://www.ncbi.nlm.nih.gov/pubmed/14693984)

Leonard DR, Farooqi MH, Myers S.

Source: Joslin Center for Diabetes, Morton Plant Mease Healthcare,

Clearwater, Florida 33756, USA.

Abstract

OBJECTIVE:

Diabetic peripheral neuropathy (DPN) has been thought to be progressive

and irreversible. Recently, symptomatic reversal of DPN was reported after

treatments with a near-infrared medical device, the Anodyne Therapy System

(ATS). However, the study was not controlled nor was the investigator

blinded. We initiated this study to determine whether treatments with the ATS

would decrease pain and/or improve sensation diminished due to DPN under a

sham-controlled, double-blind protocol.

RESEARCH DESIGN AND METHODS:

Tests involved the use of the 5.07 and 6.65 Semmes Weinstein monofilament

(SWM) and a modified Michigan Neuropathy Screening Instrument (MNSI).

Twenty-seven patients, nine of whom were insensitive to the 6.65 SWM and 18 who

were sensitive to this filament but insensitive to the 5.07 SWM, were

studied. Each lower extremity was treated for 2 weeks with sham or active ATS,

and then both received active treatments for an additional 2 weeks.

RESULTS:

The group of 18 patients who could sense the 6.65 SWM but were insensitive

to the 5.07 SWM at baseline obtained a significant decrease in the number

of sites insensate after both 6 and 12 active treatments (P < 0.02 and

0.001). Sham treatments did not improve sensitivity to the SWM, but subsequent

active treatments did (P < 0.002). The MNSI measures of neuropathic

symptoms decreased significantly (from 4.7 to 3.1; P < 0.001). Pain reported on

the 10-point visual analog scale decreased progressively from 4.2 at entry to

3.2 after 6 treatments and to 2.3 after 12 treatments (both P < 0.03). At

entry, 90% of subjects reported substantial balance impairment; after

treatment, this decreased to 17%. However, among the group of nine patients

with

greater sensory impairment measured by insensitivity to the 6.65 SWM at

baseline, improvements in sensation, neuropathic symptoms, and pain reduction

were not significant.

CONCLUSIONS:

ATS treatments improve sensation in the feet of subjects with DPN, improve

balance, and reduce pain.